rethinkPeptides Search
Menu
Study breakdown

Alpha-MSH Peptides (Including KPV) as a New Class of Anti-Inflammatory and Immune Drugs

ReviewModerate evidence
The takeaway

Alpha-MSH-derived peptides including KPV represent a new anti-inflammatory and immunomodulating drug class, working through NF-κB inhibition, Treg generation, and melanocortin receptor-independent pathways across multiple inflammatory conditions.

Key finding

Alpha-MSH-derived peptides (KPV, ACTH fragments) constitute a new anti-inflammatory drug class operating through NF-κB inhibition, regulatory T-cell i

What the researchers found

Alpha-MSH-derived peptides (KPV, ACTH fragments) constitute a new anti-inflammatory drug class operating through NF-κB inhibition, regulatory T-cell induction, and melanocortin receptor-dependent/independent pathways — applicable to IBD, arthritis, allergic, and neuroinflammatory diseases.

Why it matters

Relevant for kpv, inflammation, immune-function.

How the study worked

review study on kpv, inflammation.

What this study cannot tell us

See abstract.

How to read the evidence

moderate evidence.

When this study was published

Published in 2007.

The bigger picture

Advances peptide research.

Questions still open

  • Further research needed.
  • Clinical translation to evaluate.

Common questions

What was studied?
Alpha-MSH Peptides (Including KPV) as a New Class of Anti-Inflammatory and Immune Drugs
What was found?
Alpha-MSH-derived peptides including KPV represent a new anti-inflammatory and immunomodulating drug class, working through NF-κB inhibition, Treg generation, and melanocortin receptor-independent pathways across multiple inflammatory conditions.

Read the original research

alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs.

Annals of the rheumatic diseases, 66 Suppl 3(Suppl 3), iii52-5

Citation

Luger, Thomas A; Brzoska, Thomas. (2007). alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs.. Annals of the rheumatic diseases, 66 Suppl 3(Suppl 3), iii52-5.